A.R.T. Advisors’s Myriad Genetics MYGN Stock Holding History

A.R.T. Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-14,100	Closed	-$410K	–	1504
2018 Q4	$410K	Buy	+14,100	New	+$507K	0.03%	807
2018 Q2	–	Sell	-19,100	Closed	-$564K	–	1649
2018 Q1	$564K	Buy	+19,100	New	+$646K	0.02%	905
2017 Q2	–	Sell	-68,200	Closed	-$1.31M	–	1610
2017 Q1	$1.31M	Buy	68,200 +19,300	+39%	+$342K	0.06%	463
2016 Q4	$815K	Buy	+48,900	New	+$885K	0.05%	548
2016 Q3	–	Sell	-119,317	Closed	-$3.65M	–	978
2016 Q2	$3.65M	Buy	119,317 +105,300	+751%	+$3.66M	0.18%	146
2016 Q1	$524K	Sell	14,017 -82,000	-85%	-$3.09M	0.02%	844
2015 Q4	$4.14M	Buy	96,017 +79,968	+498%	+$3.38M	0.2%	117
2015 Q3	$601K	Buy	+16,049	New	+$570K	0.02%	801
2014 Q1	–	Sell	-95,867	Closed	-$2.01M	–	1483
2013 Q4	$2.01M	Sell	95,867 -37,612	-28%	-$951K	0.11%	272
2013 Q3	$3.14M	Sell	133,479 -61,983	-32%	-$1.76M	0.17%	171
2013 Q2	$5.25M	Buy	+195,462	New	+$5.67M	0.17%	171

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

A.R.T. Advisors's MYGN Position: Q1 2019 in Review

A.R.T. Advisors sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 14,100 shares — an estimated $410K sold.

A.R.T. Advisors first reported a position in MYGN in Q2 2013 and held it in 11 quarters. The position peaked at $5.25M in Q2 2013. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

A.R.T. Advisors reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
A.R.T. Advisors sold 14,100 Myriad Genetics shares in Q1 2019, an estimated $410K.
A.R.T. Advisors first reported a position in Myriad Genetics in Q2 2013 and held it in 11 quarters.
A.R.T. Advisors's Myriad Genetics position peaked at $5.25M in Q2 2013.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.